PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 22, 2026Clinical and Molecular Hepatology1 citationsOpen Access

ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling

View Full Paper
BTBaorui TaoCYChenhe YiBZBo Zhang

Key Points

  • The research aims to explore the role of ERBB3 in limiting the effectiveness of regorafenib in HCC after TKI therapies.
  • Evaluated the impact of ERBB3 blockade on regorafenib efficacy
  • Compared responses in HCC models with prior TKI resistance
  • Analyzed HIF1A-ABCB1 signaling pathways
  • ERBB3 was identified as a significant resistance factor to regorafenib.
  • Inhibition of ERBB3 increased sensitivity to regorafenib after TKI resistance.
  • Disruption of HIF1A-ABCB1 signaling correlated with enhanced drug response.

Abstract

This study revealed that ERBB3 was a key resistance factor driving limited efficacy to sequential regorafenib, but also an effective therapeutic target whose inhibition enhanced regorafenib sensitivity after sorafenib or lenvatinib resistance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tao et al. (2026) studied this question.

synapsesocial.com/papers/6971bdcf642b1836717e27adhttps://doi.org/10.3350/cmh.2025.0972
Ask AI
Helpful
Bookmark
Share
View Full Paper